Epidemiology of BK virus in renal allograft recipients: Independent risk factors for bk virus replication

Transplantation

Volumn 86, Issue 4, 2008, Pages 521-528

  Dadhania, Darshana ^a,b   Snopkowski, Catherine ^a   Ding, Ruchuang ^a   Muthukumar, Thangamani ^a   Chang, Christina ^a   Aull, Meredith ^a   Lee, Jun ^a,b   Sharma, Vijay K ^a,b   Kapur, Sandip ^a   Suthanthiran, Manikkam ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b ROGOSIN INSTITUTE   (United States)

Author keywords

BK virus; Kidney transplantation; Risk factors

Indexed keywords

BASILIXIMAB; CD103 ANTIGEN; CYCLOSPORIN; GRANZYME B; MESSENGER RNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN VP1; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BK VIRUS; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STEROID THERAPY; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS REPLICATION; ALLOTRANSPLANTATION; FOLLOW UP; GENETICS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PHYSIOLOGY; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RISK FACTOR; TIME; VIROLOGY;

ADULT; AGED; BK VIRUS; FEMALE; FOLLOW-UP STUDIES; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYOMAVIRUS INFECTIONS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VIRUS REPLICATION;

EID: 52449116522     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817c6447     Document Type: Article

References (32)

1. Imperiale MJ, Major EO. Polyomaviruses. In: Knipe D, Howley P, eds. Fields virology, vol 2 [ed. 5]. Philadelphia, Lippincott Williams & Wilkins 2007, p 2263.
2. Shah KV. Polyomaviruses. In: Fields B, Knipe D, Howley P, eds. Fields virology, vol2 [ed. 3]. Philadelphia, Lippincott-Raven Publishers 1996, p 2027.
3. Boldorini R, Veggiani C, Barco D, et al. Kidney and urinary tract poly-omavirus infection and distribution: Molecular biology investigation of 10 consecutive autopsies. Arch Pathol Lab Med 2005; 129: 69.
4. Jin L, Gibson PE, Booth JC, et al. Genomic typing of BKvirus in clinical specimens by direct sequencing of polymerase chain reaction products. J Med Virol 1993; 41: 11.
5. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277.
6. Nebuloni M, Tosoni A, Boldorini R, et al. BK virus renal infection in a patient with the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1999; 123: 807.
7. Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67: 103.
8. Vasudev B, Hariharan S, Hussain SA, et al. BK virus nephritis: Risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68: 1834.
9. Trofe J, Hirsch HH, Ramos E. Polyomavirus-associated nephropathy: Update of clinical management in kidney transplant patients. Transpl Infect Dis 2006; 8: 76.
10. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy inrenal-transplant recipients. N Engl J Med 2002; 347: 488.
11. Ginevri F, De Santis R, Comoli P, et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: A single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 2003; 75: 1266.
12. Hirsch H, Suthanthiran M. The natural history, risk factors and outcomes of polyomavirus BK-associated nephropathy after renal transplantation. Nat Clin Pract Nephrol 2006; 2: 240.
13. Moens U, Subramaniam N, Johansen B, et al. A steroid hormone response unit in the late leader of the noncoding control region of the human polyomavirus BK confers enhanced host cell permissivity. J Virol 1994; 68: 2398.
14. Ding R, Medeiros M, Dadhania D, et al. Noninvasive diagnosis of BK virus nephritisby measurement of messenger RNA for BK virus VP1 in urine. Transplantation 2002; 74: 987.
15. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and gran-zyme B in urine. N Engl J Med 2001; 344: 947.
16. Ding R, Li B, Muthukumar T, et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation 2003; 75: 1307.
17. Muthukumar T, DadhaniaD, DingR, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353:2342.
18. Dugan AS, Eash S, Atwood WJ. Update on BK virus entry and intracellular trafficking. Transpl Infect Dis 2006; 8: 62.
19. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582.
20. Drachenberg CB, Hirsch HH, Papadimitriou JC, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: A prospective evaluation. Transplantation 2007; 84: 323.
21. Viscount HB, Eid AJ, Espy MJ, et al. Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation 2007; 84: 340.
22. Basse G, Mengelle C, Kamar N, et al. Prospective evaluation of BK virus DNAemia in renal transplant patients and their transplant outcome. Transplant Proc 2007; 39: 84.
23. Pavlakis M, Mandelbrot D, Karp S, et al. "BK Virus Screening and Outcomes in a Steroid Withdrawal (SW) and Steroid Continuation (SB) in Kidney Transplantation." Abstract # SA-FC033, 2005 Renal Week of American Society of Nephrology. J Am Soc Nephrol 2005; 16(suppl 2):89A
24. Lipshutz GS, Mahanty H, Feng S, et al. BKV in simultaneous pancreas-kidney transplant recipients: A leading cause of renal graft loss in first 2 years post-transplant. Am J Transplant 2005; 5: 366.
25. Gupta G, Shapiro R, Thai N, et al. Low incidence of BK virus nephropathy after simultaneous kidney pancreas transplantation. Transplantation 2006; 82: 382.
26. Cosio FG, Am H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: Assessment of efficacy by protocol biopsies. Transplantation 2007; 83: 411.
27. Kagi D, Ledermann B, Burki K, et al. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 1996; 14:207.
28. Hadley GA, Bartlett ST, Via CS, et al. The epithelial cell-specific inte-grin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL. J Immunol 1997; 159: 3748.
29. Robertson H, Wong WK, Talbot D, et al. Tubulitis after renal transplantation: Demonstration of an association between CD103+ T cells, transforming growth factor beta1 expression and rejection grade. Transplantation 2001; 71: 306.
30. Sharma VK, Bologa RM, Xu GP, et al. Intragraft TGF-beta 1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996; 49: 1297.
31. Mas VR, Maluf DG, Archer KJ, et al. Study of mRNA growth factors in urinary cells of kidney transplant recipients as predictors of chronic allograft nephropathy. Transplantation 2005; 80: 1686.
32. Thomas A, Dropulic LK, Rahman MH, et al. Ureteral stents: A novel risk factor for polyomavirus nephropathy. Transplantation 2007; 84:433.